Alector, Inc. (ALEC) is a Biotechnology company in the Healthcare sector, currently trading at $2.41. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is ALEC = $3 (+34.9% upside).
Valuation: ALEC trades at a trailing Price-to-Earnings (P/E) of -1.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.38.
Financials: revenue is $21M, -34.3%/yr average growth. Net income is $143M (loss), growing at -3.1%/yr. Net profit margin is -679.2% (negative). Gross margin is 54.1% (-39.6 pp trend).
Balance sheet: total debt is $36M against $31M equity (Debt-to-Equity (D/E) ratio 1.18, moderate). Current ratio is 3.83 (strong liquidity). Debt-to-assets is 12.4%. Total assets: $293M.
Analyst outlook: 8 / 14 analysts rate ALEC as buy (57%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 97/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 75/100 (Pass), Moat 35/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
